The research team, led by Yunxiang Wan of the Max Planck Institute for Demographic Research in Rostock, together with Marwân-al-Qays Bousmah and Marília R. Nepomuceno, drew on the Chinese Longitudinal Healthy Longevity Survey, one of the largest ongoing studies of its kind in the world. Covering the period from 2002 to 2018, the survey follows thousands of older Chinese adults across repeated interviews, recording not only whether they survive from one wave to the next but how they assess their own lives. The researchers used this rich dataset to estimate what demographers call happy life expectancy: the expected number of years a person at a given age will live, and of those, how many will be spent in a state of happiness.

Technically, the study employs a cohort-based multistate life table method, an approach that deserves unpacking because it represents a methodological advance over most previous work. Traditional healthy life expectancy calculations typically rely on period measures, blending mortality rates and happiness prevalence from a single point in time as if today’s older population would experience tomorrow’s conditions. The multistate framework, by contrast, treats life as a set of transitions: individuals can move between a happy state and an unhappy state, and eventually to death, with probabilities estimated from the observed data. By structuring the analysis around birth cohorts, the researchers could compare people born roughly ten years apart as they moved through the same age ranges, isolating genuine generational change from the noise of period fluctuations.

Because the survey data do not follow each cohort from birth to death, the authors estimated what they term partial-cohort happy life expectancies, covering specific age ranges rather than full lifespans. This is a careful and honest solution to a common data limitation in longitudinal ageing studies. The core comparison pits paired cohorts against each other: for each age range examined, the experience of the earlier-born cohort is set against that of the later-born cohort a decade younger. If the later cohort spends a larger fraction of its expected years happy, that is evidence of real generational improvement rather than a statistical artifact of comparing different ages at different calendar times.

The headline finding is striking. Across all the age ranges examined, later-born cohorts of older Chinese adults showed statistically significant increases in the proportion of life spent happy. Crucially, the mechanism behind this improvement matters. The gains came primarily from an expansion in the absolute number of happy years, while total life expectancy itself remained largely stable across cohorts. In other words, these generations were not living dramatically longer, but they were living happier within roughly the same span of years. This combination, more happy years without more total years, is precisely what researchers call compression of unhappiness: the unhappy portion of life is being squeezed into a smaller and smaller window, typically pushed toward the very end of life.

The concept of compression is central to modern longevity science. For decades, researchers have debated whether added years of life come bundled with added years of illness and dependency, a scenario known as expansion of morbidity, or whether the burden of poor health is compressed into a shorter terminal period. Evidence has been mixed across countries and across measures of health. By shifting the outcome from physical health to subjective wellbeing, this study adds a new dimension to that debate. A society can, in principle, compress disability while leaving misery intact, or extend physical health while emotional suffering lingers. The Chinese evidence suggests that, at the population level, the emotional dimension has been improving in the favorable direction, with unhappiness increasingly concentrated at the end of life rather than spread across the older years.

But the study’s second major finding tempers any celebratory reading. The cohort improvements were unevenly distributed across the population in ways that mirror, and in some cases amplify, existing social inequalities. Women experienced larger gains than men in both absolute and relative terms. This is notable because women in many societies report lower levels of subjective wellbeing than men despite living longer, a paradox sometimes attributed to widowhood, disability, and economic insecurity in old age. In China, the analysis found that women’s gains were large enough to reverse an initial disadvantage in happy life expectancy, meaning that earlier cohorts of women could expect fewer happy years than men, while later cohorts overtook them. For a country where older women have historically faced structural disadvantages, this reversal is a significant demographic shift.

The socioeconomic gradient is equally consequential. Urban residents and those with formal education saw greater improvements in happy longevity than their rural and less-educated counterparts. This pattern suggests that the benefits of China’s rapid economic development over the study period, which encompassed extraordinary growth in incomes, pensions, healthcare coverage, and infrastructure, flowed disproportionately to groups already better positioned to take advantage of them. Rural older adults, who often lack adequate pension coverage and depend on family support or continued labor, and those who never entered the formal education system, appear to have been left behind in the happiness transition. The result is a widening gap in happy life expectancy between social groups, a trend that echoes findings on healthy life expectancy in many countries but is especially sharp given the pace of change in China.

These findings arrive at a critical policy moment. China’s population is ageing faster than almost any in history, driven by decades of low fertility and rising longevity, and the country’s old-age support systems are under mounting strain. If the additional years older Chinese people are living were years of misery, the fiscal and social costs of ageing would be compounded by an epidemic of late-life suffering. The compression of unhappiness documented here offers a more optimistic baseline: the ageing of the population is not, on current trends, synonymous with a growing mass of unhappy elders. Yet the widening disparities complicate that picture. A national average that conceals a growing divide between urban educated women thriving in their later years and rural uneducated men struggling through them is a fragile foundation for policy planning. Pension adequacy, rural healthcare access, and educational expansion all emerge, implicitly, as levers of happy longevity, not merely of economic policy.

The study also carries a broader methodological message for the international research community. Measuring happy life expectancy at all remains rare, and doing so with a cohort perspective is rarer still. Most national statistics systems track life expectancy with great precision but treat subjective wellbeing as a soft afterthought, if they track it at all. This analysis demonstrates that wellbeing can be integrated rigorously into the demographic toolkit, yielding estimates that are comparable across groups and over time. As other societies with rapidly ageing populations, from Japan to Italy to the United States, confront the same question of whether longer lives are better lives, the Chinese experience documented by Wan and colleagues offers both a template for measurement and a cautionary tale: happiness in old age can improve generation after generation, but without deliberate attention to equity, the happy years may belong mostly to those who need them least.

Subject of Research: Trends in happy life expectancy and socioeconomic inequality among older adults in China, 2002–2018

Article Title: Are older adults in China living longer happy years? A cohort-based multistate analysis, 2002–2018

Article References: Wan, Y., Bousmah, M.-A.-Q., & Nepomuceno, M. R. (2026). Are older adults in China living longer happy years? A cohort-based multistate analysis, 2002–2018. Genus. https://doi.org/10.1186/s41118-026-00298-z

Image Credits: AI Generated

DOI: 10.1186/s41118-026-00298-z

Keywords: happy life expectancy, population ageing, China, cohort analysis, multistate life table, compression of morbidity, subjective wellbeing, socioeconomic inequality, older adults, gender differences, longitudinal survey, demography

The new analysis, led by researchers working at the intersection of demography, gerontology, and health economics, proposes that the epidemiological transition should be reinterpreted through the lens of increasing returns. In economics, a process exhibits increasing returns when each additional unit of effort or investment yields proportionally greater benefits, at least over a relevant range. Classical public health problems often display the opposite property, diminishing returns: the first doses of a vaccine or the first clean water systems deliver enormous gains, but as coverage approaches completeness, each marginal improvement costs more and buys less. Infectious disease control, malaria eradication, and even tobacco taxation eventually run into this wall of diminishing marginal benefit. Aging-related diseases, the authors argue, behave in precisely the reverse manner.

The empirical foundation for this claim comes from a systematic reframing of the global disease burden by the age at which conditions occur. Rather than grouping diseases by their biological system, their mode of transmission, or their chronicity, the researchers sorted conditions by whether and when they arise along the human lifespan, with a particular focus on those whose incidence rises steeply with age. When the global burden of disease is sliced this way, a striking pattern emerges: aging-related diseases now dominate the total health burden not only in wealthy nations such as Japan, Germany, and the United States, but in every income group, including low- and middle-income countries that are still contending with substantial infectious disease loads. This dominance is not a distant projection; it is the present reality of global health.

This finding alone is significant, because it dismantles a persistent assumption in global health policy that chronic, aging-related conditions are a problem that can be deferred until after the infectious disease agenda is complete. The data show that there is no queue. Countries do not graduate from infection to aging-related illness in a tidy sequence; instead, aging-related diseases have already overtaken every other category of disease burden worldwide, even where HIV, tuberculosis, and malaria remain serious concerns. Policymakers who continue to treat aging-related diseases as a rich-country preoccupation are, in effect, planning for a world that no longer exists. The double burden of disease that many nations face is not transitional but structural, and the aging-related component of that burden is the larger half.

The deeper novelty of the paper, however, lies in its economic characterization of these diseases. The authors identify what they describe as a unique and underappreciated property: aging-related diseases exhibit increasing returns to tackling them. The more a society invests in preventing, delaying, or treating the conditions of aging, the greater the gains it reaps, not merely in aggregate but at the margin. The reasoning follows from the interconnected biology of aging itself. Aging is the single largest risk factor for a vast constellation of conditions, including cardiovascular disease, most cancers, Alzheimer’s disease and other dementias, type 2 diabetes, osteoporosis, macular degeneration, and frailty. These conditions do not occur independently; they share upstream mechanisms, from cellular senescence and chronic inflammation to mitochondrial dysfunction, stem cell exhaustion, and the accumulation of molecular damage across the genome and proteome.

Because these mechanisms are shared, progress against one aging-related disease tends to make progress against others easier and more valuable. Targeting the biology of aging directly, for example by clearing senescent cells, modulating nutrient-sensing pathways, or extending healthspan through interventions validated in model organisms, can reduce risk across multiple disease categories simultaneously. Each success compounds the value of the next. A therapy that delays aging by even a modest margin would delay the onset of nearly every chronic disease at once, an effect that researchers have estimated could be worth tens of trillions of dollars in health and economic value for the United States alone, and proportionally more at the global scale. Unlike single-disease campaigns that exhaust the easiest gains first, geroscience-informed interventions improve the substrate on which all subsequent medical progress operates, so the marginal benefit of additional effort rises rather than falls.

The reframing also has profound implications for how the success of the epidemiological transition should be measured. In the classical account, the compression of morbidity, shortening the period of illness at the end of life, has proven difficult to achieve, and many observers have concluded that longer lives necessarily mean longer periods of chronic disease. The increasing-returns perspective offers a different account: the health challenges of extended lifespans are not an inevitable consequence of success against infectious disease, but a solvable problem whose difficulty actually decreases as investment grows. Delaying aging compresses morbidity by shifting the onset of multiple diseases later and often faster than it extends the final period of severe illness. Populations with longer healthspans are also more productive, more independent, and less costly to health systems, generating fiscal returns that reinforce the original investment, a virtuous cycle that diminishing-returns diseases cannot offer.

The authors are careful to note that recognizing increasing returns does not mean neglecting infectious diseases, maternal health, or childhood conditions, which still demand sustained investment and where coverage gaps remain a moral and practical emergency. Rather, the argument is about prioritization and framing. If aging-related diseases dominate the global burden in every income group, and if they uniquely reward additional effort with accelerating gains, then the current allocation of research funding, which still directs the overwhelming majority of biomedical resources toward individual late-stage diseases rather than the shared biology of aging, looks difficult to defend. Treating each chronic disease in isolation, the paper suggests, is analytically equivalent to treating each symptom of a single systemic condition as a separate ailment, fragmenting effort precisely where integration would be most rewarded.

The practical agenda that follows is ambitious but concrete. It includes accelerating the translation of geroscience discoveries, such as senolytic drugs, metformin and rapamycin analogues, and other interventions that target aging mechanisms, into large-scale clinical trials designed around aging itself rather than around individual end-stage diseases. It includes regulatory reform, since agencies currently lack approval pathways for therapies whose indication is aging rather than a named disease. And it includes a demographic and economic research program that treats healthspan extension as measurable infrastructure, with returns that can be quantified, projected, and incorporated into national planning. Countries that move early, the analysis implies, will capture compounding advantages in workforce productivity, healthcare sustainability, and healthy longevity that late movers will struggle to match.

What emerges from this reframing is a fundamentally more hopeful story than the one embedded in the traditional epidemiological transition. Longer lives are not a Pyrrhic victory that simply swaps infectious scourges for chronic suffering. They are the precondition for a form of medical progress whose returns increase with scale: every year of delayed aging reduces the burden of many diseases at once, strengthens the case for further investment, and raises the ceiling of what future interventions can achieve. The transition that global health has already made, from a world of early death to a world of long life, has created the conditions for a second transition, from treating the diseases of aging one by one to addressing their shared roots. Recognizing that this second transition offers increasing rather than diminishing returns may prove to be one of the most consequential ideas in modern public health.

Subject of Research: Reframing the epidemiological transition as increasing returns to tackling aging-related diseases

Article Title: Reframing the epidemiological transition as increasing returns to tackling aging-related diseases

Article References: Ashwin, J., Bloom, D. E., Lee, N., Piot, P., & Scott, A. J. (2026). Reframing the epidemiological transition as increasing returns to tackling aging-related diseases. Nature Aging. https://doi.org/10.1038/s43587-026-01210-2

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01210-2

Keywords: epidemiological transition, aging-related diseases, global burden of disease, geroscience, increasing returns, healthspan, non-communicable diseases, biology of aging, health economics, longevity, public health policy, compression of morbidity